Rivoceranib
Sources
registry, as of 2026-11-07
https://pubmed.ncbi.nlm.nih.gov/37643133/
A Phase II Trial of Rivoceranib for Recurrent or Metastatic Adenoid Cystic Carcinoma, Clin Cancer Res, 11.14.2023, PMID 37643133 (publication abstract; opened 2026-10-27) and registry results NCT04119453 (posted 07.30.2026): 80 enrolled, 72 evaluable, 700 mg once daily; ORR 15.3% investigator and 9.7% independent review; median DoR 14.9 and 7.2 months; median PFS 9.0 months; grade 3 or higher TRAEs 70.0% (hypertension 42.5%); dose modifications 85.0%; discontinued for toxicity 20.0% (16 patients); four grade 5 events. Registry (all 80): ORR 13.8% (95% CI 7.1 to 23.3) investigator, 8.8% independent review; 12-month PFS 37.3%; serious AEs 32 of 80.
Brief source A24
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT04119453
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
ClinicalTrials.gov API v2 record, retrieved 2026-11-07